恒瑞医药：HRS-2329片获得药物临床试验批准通知书

Core Insights - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for the clinical trial of HRS-2329 tablets, an innovative anti-tumor drug developed by the company [1] - HRS-2329 tablets have shown promising anti-tumor activity in preclinical animal models and are intended for the treatment of advanced solid tumors with RAS mutations or amplifications [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] - The total research and development investment for the HRS-2329 project has reached approximately 60.15 million yuan [1]